Sponsored by
Join Updown |  forgot?
You need to upgrade your Flash Player

BIODELIV SCIENCES INTL (BDSI) 4.12 red arrow -$0.04 (-0.96%) 09:09PM (15 mins delay)


Spectrum Pharma: Post-Zevalin Approval Sales Should Ramp Up

Sep 11, 2009 - 5:49 AM EDT

As many, who have followed and/or invested in Spectrum Pharmaceuticals (SPPI), know Zevalin® was finally (and thankfully) approved last Friday, September 4, by the FDA for first-line consolidation use in patients with non-Hodgkins lymphoma (NHL).

PRELIMINARY FACTS


Complete Story »

Source: Seeking Alpha (Sep 11, 2009 - 5:49 AM EDT)



Make a suggestion for this page

Investing Channel Logo

Data powered by QuoteMedia (Terms of Use). Data delayed 15 minutes unless otherwise indicated.